MannKind Corp Ownership
| MNKD Stock | USD 3.93 0.11 2.88% |
Shares in Circulation | First Issued 2003-03-31 | Previous Quarter 290.6 M | Current Value 320.9 M | Avarage Shares Outstanding 107.4 M | Quarterly Volatility 102.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MannKind Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. MannKind Stock Ownership Analysis
About 59.0% of the company shares are owned by institutional investors. The company last dividend was issued on the 3rd of March 2017. MannKind Corp had 1:5 split on the 3rd of March 2017. MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. Mannkind Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 348 people. To find out more about MannKind Corp contact Michael PharmD at 818 661 5000 or learn more at https://www.mannkindcorp.com.Besides selling stocks to institutional investors, MannKind Corp also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different MannKind Corp's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align MannKind Corp's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
MannKind Corp Quarterly Liabilities And Stockholders Equity |
|
MannKind Corp Insider Trades History
Only 1.66% of MannKind Corp are currently held by insiders. Unlike MannKind Corp's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against MannKind Corp's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of MannKind Corp's insider trades
MannKind Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MannKind Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MannKind Corp backward and forwards among themselves. MannKind Corp's institutional investor refers to the entity that pools money to purchase MannKind Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Advisers, Llc | 2025-03-31 | 3.7 M | Dimensional Fund Advisors, Inc. | 2025-03-31 | 3.5 M | Nuveen, Llc | 2025-03-31 | 3.4 M | Two Sigma Investments Llc | 2025-03-31 | 3.4 M | Qube Research & Technologies | 2025-03-31 | 3.2 M | Tsp Capital Management Group/llc | 2025-03-31 | 2.8 M | Arrowstreet Capital Limited Partnership | 2025-03-31 | 2.7 M | Northern Trust Corp | 2025-03-31 | 2.7 M | Parkman Healthcare Partners Llc | 2025-03-31 | 2.5 M | Blackrock Inc | 2025-03-31 | 24.5 M | Vanguard Group Inc | 2025-03-31 | 17.3 M |
MannKind Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MannKind Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on MannKind Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MannKind Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MannKind Corp Outstanding Bonds
MannKind Corp issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MannKind Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MannKind bonds can be classified according to their maturity, which is the date when MannKind Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MannKind Corp is a strong investment it is important to analyze MannKind Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MannKind Corp's future performance. For an informed investment choice regarding MannKind Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MannKind Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade MannKind Stock refer to our How to Trade MannKind Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MannKind Corp. If investors know MannKind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MannKind Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.089 | Earnings Share 0.1 | Revenue Per Share 1.053 | Quarterly Revenue Growth 0.182 | Return On Assets 0.1097 |
The market value of MannKind Corp is measured differently than its book value, which is the value of MannKind that is recorded on the company's balance sheet. Investors also form their own opinion of MannKind Corp's value that differs from its market value or its book value, called intrinsic value, which is MannKind Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MannKind Corp's market value can be influenced by many factors that don't directly affect MannKind Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MannKind Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if MannKind Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MannKind Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.